Literature DB >> 16173253

Favorable outcomes with tacrolimus in two patients with refractory interstitial lung disease associated with polymyositis/dermatomyositis.

S Ochi1, T Nanki, K Takada, F Suzuki, Y Komano, T Kubota, N Miyasaka.   

Abstract

Two cases of progressive interstitial lung disease associated with polymyositis/dermatomyositis are presented. Both patients were refractory to conventional therapy with high-dose corticosteroids, cyclosporine, and intermittent pulse cyclophosphamide, and thus a therapeutic trial of tacrolimus was instituted. Tacrolimus was markedly effective in achieving subjective, laboratory and radiographic improvement in both patients.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16173253

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  19 in total

Review 1.  Treatment of inflammatory myopathy: emerging therapies and therapeutic targets.

Authors:  Siamak Moghadam-Kia; Rohit Aggarwal; Chester V Oddis
Journal:  Expert Rev Clin Immunol       Date:  2015-08-27       Impact factor: 4.473

Review 2.  Characteristic features of tacrolimus-induced lung disease in rheumatoid arthritis patients.

Authors:  Takanori Sasaki; Wataru Nakamura; Shigeko Inokuma; Erika Matsubara
Journal:  Clin Rheumatol       Date:  2015-02-03       Impact factor: 2.980

Review 3.  Interstitial lung disease in myositis: clinical subsets, biomarkers, and treatment.

Authors:  Tsuneyo Mimori; Ran Nakashima; Yuji Hosono
Journal:  Curr Rheumatol Rep       Date:  2012-06       Impact factor: 4.592

Review 4.  Treatment in myositis.

Authors:  Chester V Oddis; Rohit Aggarwal
Journal:  Nat Rev Rheumatol       Date:  2018-03-29       Impact factor: 20.543

Review 5.  Treatment of refractory polymyositis and dermatomyositis.

Authors:  Steven R Ytterberg
Journal:  Curr Rheumatol Rep       Date:  2006-06       Impact factor: 4.592

Review 6.  Interstitial lung disease in connective tissue diseases: evolving concepts of pathogenesis and management.

Authors:  Flavia V Castelino; John Varga
Journal:  Arthritis Res Ther       Date:  2010-08-23       Impact factor: 5.156

Review 7.  Effects of tacrolimus on dermatomyositis and polymyositis: a prospective, open, non-randomized study of nine patients and a review of the literature.

Authors:  Shiro Matsubara; Koichi Kondo; Keizo Sugaya; Kazuhito Miyamoto
Journal:  Clin Rheumatol       Date:  2012-08-12       Impact factor: 2.980

8.  Connective Tissue Disease-associated Interstitial Lung Disease: A review.

Authors:  Markus Gutsche; Glenn D Rosen; Jeffrey J Swigris
Journal:  Curr Respir Care Rep       Date:  2012-09-21

Review 9.  [Interstitial lung disease in polymyositis/dermatomyositis].

Authors:  A Schnabel
Journal:  Z Rheumatol       Date:  2013-04       Impact factor: 1.372

Review 10.  Idiopathic inflammatory myopathies: current and future therapeutic options.

Authors:  Heinz Wiendl
Journal:  Neurotherapeutics       Date:  2008-10       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.